Answers are grounded in this paper and cite their sources.
Tryptophan (Trp) is required by both immune and tumor cells for protein synthesis and key metabolic pathways. While immune cells rely on Trp for proliferation and function, tumor cells exploit IDO1-mediated Trp degradation to evade immune surveillance. However, clinical trials have demonstrated limited efficacy of IDO1 inhibitors, likely due to insufficient tumor targeting and immune evasion strategies within the tumor microenvironment (TME). Here, we explored a novel approach using intratumoral (IT) delivery of a crystallised IDO1 inhibitor designed for depot-based slow release. Using aggressive murine solid tumor models, we combined in vivo assessments of tumor growth with metabolic profiling to investigate treatment effects. Despite increased metabolite abundance in tumors, IT administration of the crystallised IDO1 inhibitor failed to control tumor growth compared to soluble formulations (subcutaneously or intravenously). Immune profiling confirmed that IDO1 blockade alone did not reverse immunosuppression in the TME. Interestingly, IT treatment with IDO1 inhibitor crystals significantly elevated nicotinamide riboside (NR) levels, suggesting tumor-intrinsic metabolic adaptation via the NAD⁺ salvage pathway. Similarly, local delivery of crystallised Trp did not suppress tumor progression. On the contrary, an excess presence of Trp enhanced tumor growth, demonstrating that Trp is also essential for tumor growth. These findings underscore the metabolic plasticity of tumors and highlight the limited therapeutic potential of IDO1 inhibition, even with local, sustained-release strategies.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: